Introduction
Tobramycin and amikacin (BB-K8) are recent additions to the aminoglycoside group of antibiotics. Tobramycin (originally nebramycin factor 6) is a natural product, part of the complex produced by Streptomyces tenebrarius (Thompson and Presti, 1968) , and several workers have claimed that it has greater activity in vitro than gentamicin, particularly against Pseudomonas aeruginosa (Wick and Welles, 1968; Preston and Wick, 1971; Black and Griffith, 1971; Levison et al., 1972; Karney et al., 1973; Young and Hewitt, 1973) . Amikacin is a semisynthetic derivative of kanamycin (Kawaguchi et al., 1972 ) with significant activity against Ps. aeruginosa, and enhanced stability towards R-factor-mediated degradative enzymes. The toxicity of tobramycin is similar to that of gentamicin (Brummett et al., 1972) , and that of amikacin resembles that of kanamycin (Reiffenstein et al., 1973) .
Gentamicin and kanamycin are recommended by Darrell and Neale (1972) for the treatment of serious infections caused by Gram-negative bacteria. Brumfitt and Leigh (1969) studied W. BRUMFITT severe infections occurring in hospital caused by Gram-negative bacteria or staphylococci and found gentamicin to be effective. It is therefore of interest to determine whether the properties of the two newer compounds justify reconsideration of the drug of choice in such infections. It seemed logical as a preliminary step to make a comparison of the in-vitro microbiological activities of amikacin, gentamicin, kanamycin, and tobramycin, firstly, against a range of unselected clinically-isolated bacterial strains and, secondly, against organisms isolated from patients in hospital that showed resistance to one or more of the aminoglycoside antibiotics.
Methods
Antibiotics.-Kanamycin sulphate (Kantrex) was obtained from the Bristol Laboratories, who also supplied amikacin base (878 ,ug/mg). Gentamicin sulphate powder (564 ,ug/mg) was provided by Roussel Laboratories, and Eli Lilly supplied tobramycin in the form of a laboratory standard containing 1 mg of base/ml.
Bacterial Strains.-For the first part ofthe investigation strains were used that had been isolated from clinical specimens sent to the routine microbiology laboratory of this hospital. They were identified by the methods of Cowan and Steel (1965) and Ewing (1970 (CM 409) . Organisms were grown statically at 37°C for 18 hours in Hartley's digest broth (Southern Group Laboratories, London), diluted 1/100 indistilled water, and inoculated on to the plates using a multiple-inoculating device (Tarr, 1958) which delivers about 3 yl of suspension (about 3 x 10' colony-forming units). The M.I.C. was taken to be the lowest concentration of antibiotic that permitted the growth of less than four colonies after overnight incubation-that is, inhibition of at least 99-99% of the original inoculum. All M.I.C. are expressed in terms of aminoglycoside base. and knowledge of blood levels after administration of therapeutic doses of the antibiotics (see below). The superiority of amikacin is clear from these results. Sensitivities of Strains Selected for Aminoglycoside Resistance. M.I.C. for the four antibiotics against 22 strains of Enterobacteriaceae (15 E. coli, 3 Ent. cloacae, 2 Ki. pneumoniae, 1 Pr. rettgeri, and 1 Prov. stuartii) resistant to kanamycin or gentamicin and also for 15 strains of Ps. aeruginosa known to be resistant to gentamicin are shown in table III. It is apparent that amikacin is more likely to be active against aminoglycosideresistant strains than any of the other three compounds tested. The results for individual organisms show that, with few exceptions, organisms resistant to amikacin were also resistant to the other compounds.
Results

Sensitivities of Clinically-isolated
Discussion
The results presented in this paper closely parallel the data presented by most other workers on the relative activity of these four antibiotics, in that against all species except Ps. aeruginosa gentamicin was more active than tobramycin (Wick and Welles, 1968; Black and Griffith, 1971; Traub and Raymond, 1972; Karney et al., 1973; Yourassowsky et al., 1973, Young and Hewitt, 1973; Klastersky et al., 1972 Klastersky et al., , 1974 . The results obtained with amikacin are similar to those obtained by workers in the United States (Price et al., 1972 (Price et al., , 1974 Karney et al., 1973; Young and Hewitt, 1973; Yu and Washington, 1973) as amikacin and kanamycin had very similar activities, but amikacin was also active against many strains resistant to kanamycin and other aminoglycosides. Confirmation of these results seemed justified in view of the geographical variation in antimicrobial sensitivities of the various organisms tested. Furthermore, most of the previous studies neither carried out a simultaneous comparison nor tested such a wide range of clinical isolates.
Kanamycin and amikacin have been shown to have similar pharmacological and toxicological properties (Cabana and Taggart, 1973; Reiffenstein et al., 1973) , as have gentamicin and tobramycin (Brummett, 1972; Simon et al., 1973; Meyers and Hirschman, 1972; Regamey et al., 1973) . Cabana and Taggart (1973) showed that using the same doses kanamycin and amikacin both gave peak blood levels of 20 ,Lg/ml. When the relationships of geometric mean M.I.C.s to peak blood levels are considered gentamicin is seen to have the largest margin for all species except Prov. stuartii and Ps. aeruginosa. This consideration does not, however, necessarily predict the clinical effectiveness of an antibiotic. Thus, Klastersky et al. (1974) showed that gentamicin and tobramycin had a similar success rate in treating a variety of infections due to Ps. aeruginosa, even though tobramycin is more active in vitro.
Therefore, considering the good in-vitro activity of both tobramycin and amikacin these two antibiotics should be considered for comparative clinical trial with gentamicin. Whether or not either of these two new aminoglycosides will replace gentamicin, which has been shown to be highly effective in serious infections due to Gram-negative bacilli (Shimuzu, 1969; Martin et al., 1969; Marsden and Hyde, 1970; Cox and Harrison, 1971; McHenry et al., 1971; Noone et al., 1974) , depends on the outcome of such trials and whether or not bacterial resistance to gentamicin becomes a significant problem.
In conclusion, tobramycin seems closely to resemble gentamicin in its in-vitro properties, while amikacin is clearly superior to kanamycin and seems slightly better than gentamicin. In view of the value of gentamicin in the treatment of a variety of infections by Gram-negative organisms our in-vitro results indicate that amikacin deserves urgent in-vivo assessment.
